Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
23/06/2025 13:21
June 23 (Reuters) - NKGen Biotech Inc NKGN.PK: NKGEN BIOTECH ANNOUNCES INTERNATIONAL AND U.S. EXPANSION OF PHASE 1/2A TROCULEUCEL ALZHEIMER’S TRIAL WITH ACTIVATION OF CLINICAL SITES IN CANADA AND FLORIDA Source text: ID:nGNX6RT7bJ Further company coverage: NKGN.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program